Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

التفاصيل البيبلوغرافية
العنوان:	Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial
المؤلفون:	Ladenstein, R, Potschger, U, Pearson, ADJ, Brock, P, Luksch, R, Castel, V, Yaniv, I, Papadakis, V, Laureys, G, Malis, J, Balwierz, W, Ruud, E, Kogner, P, Schroeder, H, de Lacerda, AF, Beck-Popovic, M, Bician, P, Garami, M, Trahair, T, Canete, A, Ambros, PF, Holmes, K, Gaze, M, Schreier, G, Garaventa, A, Vassal, G, Michon, J, Valteau-Couanet, D
المصدر:	The Lancet. Oncology. 18(4):500-514
مصطلحات موضوعية:	Medicin och hälsovetenskap
URL الوصول:	http://kipublications.ki.se/Default.aspx?queryparsed=id:135433714
قاعدة البيانات:	SwePub

الوصف
تدمد:	14745488
DOI:	10.1016/S1470-2045(17)30070-0